- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-metastatic hormone-sensitive prostate cancer (m0HSPC)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.8MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 1.9MB)
Enzalutamide – November 2024
Enzalutamide; Capsule 40 mg; Xtandi®
Last updated
30 May 2025